Cherry Mathew, MD
Neurology · Lufkin, TXNPI 1174589790
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,315 and has fallen 53.8% since, to $608 in 2025.
Across 267 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$683
- Sunovion Pharmaceuticals Inc.$567
- Acadia Pharmaceuticals Inc$417
- Jazz Pharmaceuticals Inc.$399
- Teva Pharmaceuticals USA, Inc.$372
- Supernus Pharmaceuticals, Inc.$265
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$341%
- Food & beverage$4,88699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $683 |
| Sunovion Pharmaceuticals Inc. | 39 | $567 |
| Acadia Pharmaceuticals Inc | 24 | $417 |
| Jazz Pharmaceuticals Inc. | 11 | $399 |
| Teva Pharmaceuticals USA, Inc. | 17 | $372 |
| Supernus Pharmaceuticals, Inc. | 18 | $265 |
| Lilly USA, LLC | 15 | $236 |
| Novartis | 13 | $234 |
| SK Life Science, Inc. | 13 | $234 |
| Eisai Inc. | 13 | $203 |
| EMD Serono, Inc. | 12 | $196 |
| Amgen | 8 | $139 |
| UCB, Inc. | 7 | $135 |
| Amneal Pharmaceuticals LLC | 7 | $98 |
| Ceribell, Inc. | 1 | $86 |
| Boston Scientific | 1 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Aquestive Therapeutics, Inc. | 3 | $58 |
| GE HealthCare | 2 | $44 |
| Sanofi | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $40 |
| CSL Behring | 2 | $36 |
| Acorda Therapeutics, Inc | 2 | $34 |
| Neurelis, Inc. | 2 | $34 |
| Biogen | 2 | $33 |
| Greenwich Biosciences, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Argenx US, Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Resmed Corp | 1 | $11 |
How this compares
$4,920 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Lufkin
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.